| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to search for treatment and prevention method of molecular targeted drugs-induced dermatological side effects based on the pathological mechanism to focus the activity of STAT3. By screening assay searching chemicals resisted to decrease of phosphorylated STAT3 by sorafenib in HaCaT cells, P-VC-Mg and PGE1 were selected. Both chemicals showed resistance to sorafenib-induced apoptosis, and the efficacy of both chemicals to dermatological side effects was demonstrated by the experiment with 3D skin model. These chemicals may be able to apply as treatment and prevention method of molecular targeted drugs-induced dermatological side effects.
|
